Showing 121 - 140 results of 34,833 for search '(( 50 ((((we decrease) OR (mean decrease))) OR (nn decrease)) ) OR ( 5 we decrease ))', query time: 1.18s Refine Results
  1. 121
  2. 122
  3. 123

    Influence of Interfacial Gas Enrichment on Controlled Coalescence of Oil Droplets in Water in Microfluidics by Jianlong Wang (438075)

    Published 2019
    “…The thickness of the IGE layer decreases from 5.5 to 4.9 nm when the amount of dissolved gas decreases from 7.89 to 4.59 mg/L. …”
  4. 124
  5. 125
  6. 126

    Image1_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. …”
  7. 127

    Image2_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. …”
  8. 128

    Image3_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. …”
  9. 129

    Image4_Decreasing incidence and mortality of lung cancer in Hungary between 2011 and 2021 revealed by robust estimates reconciling multiple data sources.TIFF by Gabriella Gálffy (177759)

    Published 2024
    “…Leveraging on this methodology, we aimed at updating Hungarian lung cancer incidence estimates with an additional 5 years (2017–2021), including years affected by the COVID-19 pandemic. …”
  10. 130
  11. 131

    DataSheet_1_Circulating exosomes decrease in size and increase in number between birth and age 7: relations to fetal growth and liver fat.pdf by Marta Díaz (337207)

    Published 2023
    “…</p>Results<p>Circulating exosomes of AGAs decreased in size (on average by 4.2%) and increased in number (on average by 77%) between birth and age 7. …”
  12. 132
  13. 133
  14. 134
  15. 135
  16. 136
  17. 137

    Image 5_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

    Published 2025
    “…Moreover, 5 of the decreased autoantibodies can also be applied for supervising bone metastasis in lung adenocarcinoma. …”
  18. 138
  19. 139

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…<i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”
  20. 140

    Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

    Published 2022
    “…<i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC<sub>50</sub> = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC<sub>50</sub> = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC<sub>50</sub> = 2.29 ± 0.92 μM (MCF-7)]. …”